-
公开(公告)号：US20060269530A1
公开(公告)日：2006-11-30
申请号：US10552914
申请日：2004-02-23
申请人： Gary Clawson , Wei-Hua Pan , Ping Xin
发明人： Gary Clawson , Wei-Hua Pan , Ping Xin
CPC分类号： C12N15/1131 , A61K31/19 , A61K31/60 , A61K45/06 , C12N2310/12 , C12N2310/121 , C12N2310/14 , C12N2310/317 , Y02A50/465 , A61K2300/00
摘要： The invention provides isolated nucleic acids. For example, the invention provides isolated nucleic acids having at least one strand with both sense and antisense sequences that are complementary to each other. The invention also provides isolated nucleic acids having at least one strand that is a template for both sense and antisense sequences that are complementary to each other. In addition, the invention provides cells, viruses, and transgenic animals (e.g., transgenic non-human animals) containing one or more of the isolated nucleic acids provided herein as well as methods for using one or more of the isolated nucleic acids provided herein to reduce the level of an RNA (e.g., an mRNA) within a cell.
摘要翻译： 本发明提供分离的核酸。 例如，本发明提供了分离的核酸，其具有至少一条具有彼此互补的有义和反义序列的链。 本发明还提供具有至少一条链的分离的核酸，其是互补互补的有义和反义序列的模板。 此外，本发明提供了含有本文提供的一种或多种分离的核酸的细胞，病毒和转基因动物（例如，转基因非人动物）以及使用本文提供的一种或多种分离的核酸的方法 降低细胞内的RNA水平（例如mRNA）。
-
公开(公告)号：US20050107326A1
公开(公告)日：2005-05-19
申请号：US10935962
申请日：2004-09-08
申请人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
发明人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
IPC分类号： C12N15/09 , A61K35/74 , A61K35/76 , A61K38/00 , A61K48/00 , A61P31/04 , C08K5/20 , C08K5/29 , C12N7/00 , C12N9/00 , C12N15/113 , C12N15/74 , A01K67/00 , C07H21/02
CPC分类号： C08K5/20 , A61K38/00 , A61K48/00 , C08K5/29 , C12N15/113 , C12N15/74 , C12N2310/111 , C12N2310/12 , C12N2310/317 , C12N2799/021 , C08L69/00
摘要： The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).
摘要翻译： 本发明涉及对病原体致死的毒性试剂的发现，鉴定和表征以及将这些毒性试剂靶向病原体或病原体感染的细胞以便治疗和/或根除感染的方法。 特别地，本发明涉及针对细菌生命周期不同阶段的细菌的毒性试剂，它们单独或组合递送至细菌或细菌感染细胞。 本发明涉及对患病细胞致死的毒物剂和用于将这些毒物剂靶向病变细胞以便治疗和/或根除疾病的方法。 本发明涉及作为病原体特异性或组织特异性的启动子元件以及这些启动子元件用于实现本发明的毒性剂和/或核酶的病原体特异性或组织特异性表达的启动子元件 发明。 具体地，本发明涉及递送一种或多种有毒基因产物，反义RNA或核酶或其组合。 本发明提供了一种新的系统，通过该系统可以同时靶向多种致病性靶标以引起病原体或感染病原体的细胞的死亡。 此外，本发明对消除耐药细菌和细菌病原体具有重要的意义。 本发明提供了一种新颖的系统，通过该系统可以同时靶向多个靶标以引起患病细胞的死亡。 本发明对消除耐药性病原体（如抗生素抗性细菌）和耐药性疾病细胞（如耐药性癌细胞）具有重要意义。
-
公开(公告)号：US20060058252A1
公开(公告)日：2006-03-16
申请号：US10519122
申请日：2003-06-26
申请人： Gary Clawson , Wei-Hua Pan , Diane Thiboutot , Neil Christensen
发明人： Gary Clawson , Wei-Hua Pan , Diane Thiboutot , Neil Christensen
IPC分类号： A61K48/00
CPC分类号： C12N15/1131 , A61K31/19 , A61K31/60 , A61K38/00 , A61K45/06 , C07K14/005 , C12N7/00 , C12N2310/12 , C12N2310/121 , C12N2310/317 , C12N2710/20022 , A61K2300/00
摘要： The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers).
摘要翻译： 本发明提供了与治疗HPV感染（例如，皮肤和粘膜上皮细胞的HPV感染）和HPV相关病症（例如宫颈发育不良，HPV相关子宫颈癌，口腔粘膜乳头瘤病毒，喉乳头状瘤）有关的方法和材料。
-
公开(公告)号：US07575918B2
公开(公告)日：2009-08-18
申请号：US10935962
申请日：2004-09-08
申请人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael G. Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
发明人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael G. Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
CPC分类号： C08K5/20 , A61K38/00 , A61K48/00 , C08K5/29 , C12N15/113 , C12N15/74 , C12N2310/111 , C12N2310/12 , C12N2310/317 , C12N2799/021 , C08L69/00
摘要： The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).
摘要翻译： 本发明涉及对病原体致死的毒性试剂的发现，鉴定和表征以及将这些毒性试剂靶向病原体或病原体感染的细胞以便治疗和/或根除感染的方法。 特别地，本发明涉及针对细菌生命周期不同阶段的细菌的毒性试剂，它们单独或组合递送至细菌或细菌感染细胞。 本发明涉及对患病细胞致死的毒物剂和用于将这些毒物剂靶向病变细胞以便治疗和/或根除疾病的方法。 本发明涉及作为病原体特异性或组织特异性的启动子元件以及这些启动子元件用于实现本发明的毒性剂和/或核酶的病原体特异性或组织特异性表达的启动子元件 发明。 具体地，本发明涉及递送一种或多种有毒基因产物，反义RNA或核酶或其组合。 本发明提供了一种新的系统，通过该系统可以同时靶向多种致病性靶标以引起病原体或感染病原体的细胞的死亡。 此外，本发明对消除耐药细菌和细菌病原体具有重要的意义。 本发明提供了一种新颖的系统，通过该系统可以同时靶向多个靶标以引起患病细胞的死亡。 本发明对消除耐药性病原体（如抗生素抗性细菌）和耐药性疾病细胞（如耐药性癌细胞）具有重要意义。
-
5.发明申请Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof 审中-公开组织特异性和病原体特异性毒性剂，核酶，dnazymes和反义寡核苷酸及其使用方法公开(公告)号：US20060223774A1
公开(公告)日：2006-10-05
申请号：US11375690
申请日：2006-03-13
申请人： James Norris , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Gary Clawson , Wei-Hua Pan
发明人： James Norris , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Gary Clawson , Wei-Hua Pan
CPC分类号： C12N15/1131 , A61K38/00 , C12N15/113 , C12N15/74 , C12N2310/111 , C12N2310/12 , C12N2310/317 , C12Q1/6811 , C12Q2521/337
摘要： The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention has important implications in the eradication of drug-resistant pathogens (such as antibiotic resistant bacteria) and drug-resistant diseased cells (such as drug-resistant cancer cells).
摘要翻译： 本发明涉及对病原体致死的毒性试剂的发现，鉴定和表征以及将这些毒性试剂靶向病原体或病原体感染的细胞以便治疗和/或根除感染的方法。 特别地，本发明涉及针对细菌生命周期不同阶段的细菌的毒性试剂，它们单独或组合递送至细菌或细菌感染细胞。 本发明涉及对患病细胞致死的毒物剂和用于将这些毒物剂靶向病变细胞以便治疗和/或根除疾病的方法。 本发明涉及作为病原体特异性或组织特异性的启动子元件以及这些启动子元件用于实现本发明的毒性剂和/或核酶的病原体特异性或组织特异性表达的启动子元件 发明。 具体地，本发明涉及递送一种或多种有毒基因产物，反义RNA或核酶或其组合。 本发明提供了一种新的系统，通过该系统可以同时靶向多种致病性靶标以引起病原体或感染病原体的细胞的死亡。 此外，本发明对消除耐药细菌和细菌病原体具有重要的意义。 本发明提供了一种新颖的系统，通过该系统可以同时靶向多个靶标以引起患病细胞的死亡。 本发明对消除耐药性病原体（如抗生素抗性细菌）和耐药性疾病细胞（如耐药性癌细胞）具有重要意义。
-
公开(公告)号：US06271359B1
公开(公告)日：2001-08-07
申请号：US09291902
申请日：1999-04-14
申请人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
发明人： James Norris , Gary Clawson , Caroline Westwater , David Schofield , Michael Schmidt , Brian Hoel , Joseph Dolan , Wei-Hua Pan
IPC分类号： C07H2102
CPC分类号： C12N15/113 , A61K38/00 , A61K48/00 , C12N15/74 , C12N2310/111 , C12N2310/12 , C12N2799/021
摘要： The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention. Specifically, the invention relates to the delivery of one or more toxic gene products, antisense RNAs, or ribozymes, or combination thereof. The invention provides a novel system by which multiple pathogenic targets may be simultaneously targeted to cause the death of a pathogen, or cell infected with a pathogen. Further, the invention has important implications in the eradication of drug-resistant bacterium and bacterial pathogens. The invention provides a novel system by which multiple targets may be simultaneously targeted to cause the death of a diseased cell. The invention also has important implications in the eradication of drug-resistant pathogens and drug-resistant diseased cells (such as cancer cells).
摘要翻译： 本发明涉及对病原体致死的毒性试剂的发现，鉴定和表征以及将这些毒性试剂靶向病原体或病原体感染的细胞以便治疗和/或根除感染的方法。 特别地，本发明涉及针对细菌生命周期不同阶段的细菌的毒性试剂，它们单独或组合递送至细菌或细菌感染细胞。 本发明涉及对患病细胞致死的毒物剂和用于将这些毒物剂靶向病变细胞以便治疗和/或根除疾病的方法。 本发明涉及作为病原体特异性或组织特异性的启动子元件以及这些启动子元件用于实现本发明的毒性剂和/或核酶的病原体特异性或组织特异性表达的启动子元件 发明。 具体地，本发明涉及递送一种或多种有毒基因产物，反义RNA或核酶或其组合。 本发明提供了一种新的系统，通过该系统可以同时靶向多种致病性靶标以引起病原体或感染病原体的细胞的死亡。 此外，本发明对消除耐药细菌和细菌病原体具有重要的意义。 本发明提供了一种新颖的系统，通过该系统可以同时靶向多个靶标以引起患病细胞的死亡。 本发明也对消除耐药病原体和耐药性疾病细胞（如癌细胞）具有重要意义。
-
公开(公告)号：US07402561B2
公开(公告)日：2008-07-22
申请号：US11076680
申请日：2005-03-09
IPC分类号： A01N37/18
CPC分类号： A61K38/07 , A61K38/00 , A61K38/55 , C07K5/06191 , C07K5/0827 , Y10S514/934
摘要： In the US about ⅓ of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.
摘要翻译： 在美国，大约1/3的大学女性表现出HPV感染的证据。 发展中国家的临床问题可能更大。 除了治疗性锥体活组织检查之外，目前还没有有效的HPV感染治疗方法，其往往是复发性进行性病变。 因此，详细描述了用于治疗HPV感染的药物组合物和方法。 特别地，提供了抑制人乳头瘤病毒感染细胞生长的药物组合物，其包括糜蛋白酶或胰凝乳蛋白酶样蛋白酶的肽卤代甲基酮抑制剂和药学上可接受的载体。 优选的抑制剂是AAPFcmk。
-
公开(公告)号：US20050209150A1
公开(公告)日：2005-09-22
申请号：US11076680
申请日：2005-03-09
IPC分类号： A61K38/00 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/55 , C07K5/06 , C07K5/08 , C12Q1/70
CPC分类号： A61K38/07 , A61K38/00 , A61K38/55 , C07K5/06191 , C07K5/0827 , Y10S514/934
摘要： In the US about ⅓ of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.
摘要翻译： 在美国，大约1/3的大学女性表现出HPV感染的证据。 发展中国家的临床问题可能更大。 除了治疗性锥体活组织检查之外，目前还没有有效的HPV感染治疗方法，其往往是复发性进行性病变。 因此，详细描述了用于治疗HPV感染的药物组合物和方法。 特别地，提供了抑制人乳头瘤病毒感染细胞生长的药物组合物，其包括糜蛋白酶或胰凝乳蛋白酶样蛋白酶的肽卤代甲基酮抑制剂和药学上可接受的载体。 优选的抑制剂是AAPFcmk。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)
